<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "nelarabine inj VIAL">
<dose><value>1500</value>
<value>650</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>nelarabine inj VIAL</value>
</drugname><strength><value>5 mg/mL</value>
</strength><frequency><value>EVERY OTHER DAY</value>
<value>DAILY</value>
</frequency><instruction><value>for 3 doses. Administer dose undiluted over 2 hours.</value>
<value>for 5 consecutive days. Administer dose undiluted over 1 hour.</value>
</instruction><volume><value>50 mL</value>
</volume><units><value>mg/m2/day</value>
</units><additionalnotes><value>T-cell Lymphoblastic leukemia, T-cell lymphoblastic lymphoma. No dosage adjustments provided with manufacturer&amp;apos;s labelling; patients should be monitored closey if CrCl is less than 50 mL/minute or total bilirubin is 3 times ULN. Discontinuing treatment is recommended for neurotoxicity greater than or equal to grade 2.</value>
</additionalnotes><population><value>ADULT</value>
<value>CHILDREN </value>
</population><indicationprn></indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3323</value>
</backgroundinformation><prninformation></prninformation><ahsformularystatus><value>Formulary.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose></maximumprndose><din><value>02299925</value>
</din><type><value>Medication/IV Therapy</value>
</type></drug>